Oncology Brothers: Practice-Changing Cancer Discussions WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos
Sep 18, 2025
Dr. Balazs Halmos, a thoracic medical oncologist at Montefiore Einstein Cancer Center, joins the discussion on crucial findings from the World Conference on Lung Cancer 2025. He highlights the FLAURA2 trial, showcasing how osimertinib combined with chemotherapy enhances survival for EGFR-positive non-small cell lung cancer patients. Halmos delves into the HARMONi trial's unexpected results with a bi-specific antibody and the significance of ctDNA. He wraps up with insights on crizotinib's role in ALK-positive cases and the evolving landscape of precision oncology.
AI Snips
Chapters
Transcript
Episode notes
FLORA2 Shows Significant OS Gain
- FLORA2 showed about a one-year median overall survival benefit when adding chemotherapy to osimertinib versus osimertinib alone.
- The hazard ratio was 0.77, making the benefit both statistically significant and clinically meaningful.
Use Shared Decision-Making On Regimen Choice
- Present both FLORA2 and Mariposa adverse-event profiles to patients and use shared decision-making to choose a regimen.
- Feel empowered to stop or adjust maintenance pemetrexed if toxicity compromises quality of life.
Mariposa Versus FLORA2: Similar Benefit, Different Risks
- Mariposa and FLORA2 offer similar OS benefits but differ substantially in toxicity and administration.
- Mariposa brings infusion-related, EGFR toxicities and high venous thromboembolism risk requiring proactive supportive care.